EP MedSystems Announces Changes to Its Board of Directors
January 11 2007 - 6:00AM
Business Wire
EP MedSystems, Inc. (NASDAQ: EPMD), today announced the Company has
appointed Gerard J. Michel, to its board of directors and audit
committee. Mr. Michel is the Chief Financial Officer and Vice
President, Corporate Strategy of NPS Pharmaceuticals, Inc (�NPS�).
NPS engages in the discovery, development, and commercialization of
small molecules and recombinant proteins. The company�s product
candidates are primarily used for the treatment of bone and mineral
disorders, gastrointestinal disorders, and central nervous system
disorders. David Jenkins, EP MedSystems� Chairman stated, �We are
fortunate to add Gerry�s breadth of experience in healthcare market
segments and business models to our Board.� In addition to his NPS
experience, Mr.�Michel served as a Principal for the consulting
firm of Booz-Allen�& Hamilton from 1995 to 2002 where he worked
with medical device companies, large pharmaceutical companies,
biotech firms, and service firms. From 1988 to 1995, Mr.�Michel was
with Lederle Labs, serving in Marketing, Sales and Corporate
Development roles, both domestically and internationally.
Mr.�Michel received an M.S. degree in Microbiology and an M.B.A.
degree, both from the University of Rochester. Mr. Michel replaces
Paul Ray who passed away last week. David Bruce, EP MedSystems�
President and CEO stated, �We are all saddened by the loss of Paul
and we�ll miss his dedication and sensible counsel.� Mr. Ray was a
member of the Company�s audit, compensation and nominating
committees. Upon receiving notice of Mr. Ray�s death, EP MedSystems
notified Nasdaq it was temporarily out of compliance with Nasdaq
Marketplace Rule 4350(c)(1), which requires a majority of its board
of directors to be comprised of independent directors, and with
Nasdaq Marketplace Rule 4359(d)(2), which requires its audit
committee to consist of at least three members. With the
appointment of Mr. Michel to the Company�s board the audit
committee, Nasdaq informed the Company it has fully regained
compliance. During the period of noncompliance, there were no
actions taken by the audit committee or the board other than those
related to Mr. Michel�s appointment. About EP MedSystems EP
MedSystems develops and markets cardiac electrophysiology ("EP")
products used in visualizing, diagnosing and treating certain
cardiac rhythm disorders. The Company's EP product line includes
the EP-WorkMate� Electrophysiology Workstation, the MapMate�
Navigation Interface, the NurseMate� Remote Review Charting
Station, the EP-4� Computerized Cardiac Stimulator, fixed and
deflectable diagnostic electrophysiology catheters and related
disposable supplies, and the ViewMate� intracardiac ultrasound
catheter imaging system. For more information, visit our website at
www.epmedsystems.com. Forward Looking Statements: This Release may
contain certain statements of a forward-looking nature relating to
future events or the future financial performance of the Company.
Forward-looking statements include information concerning our
possible or assumed future results of operations and statements
preceded by, followed by or including the words �believes�,
�expects�, �anticipates�, �intends�, �plans�, �estimates�, or
similar expressions. Such forward-looking statements are based on
our management�s beliefs and assumptions and on information
currently available to our management. Such forward-looking
statements are only predictions and are subject to risks and
uncertainties that could cause actual results or events to differ
materially and adversely from the events discussed in the
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, EP MedSystems�
history of losses, uncertainty of market acceptance of our products
and level of sales, uncertainty of future profitability and future
liquidity needs; possible costs, fines or penalties that may be
incurred in connection with government inquiries and investigations
and risks regarding regulatory approvals and demand for new and
existing products, as stated in the Company�s Annual Report filed
on Form 10-K and quarterly reports filed on Form 10-Q. EP
MedSystems cautions investors and others to review the cautionary
statements set forth in this press release and in EP MedSystems�
reports filed with the Securities and Exchange Commission and
cautions that other factors may prove to be important in affecting
the EP MedSystems� business and results of operations. Readers are
cautioned not to place undue reliance on this press release and
other forward-looking statements, which speak only as of the date
of this press release. EP MedSystems undertakes no obligation to
publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date of this press release or to reflect
the occurrence of unanticipated events.
EP Medsystems (MM) (NASDAQ:EPMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
EP Medsystems (MM) (NASDAQ:EPMD)
Historical Stock Chart
From Jul 2023 to Jul 2024